KAS
CRSP icon

Kemnay Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Kemnay Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.5K Buy
767
+484
+171% +$25.5K 0.01% 372
2025
Q4 		$14.8K Buy
+283
New +$16.9K ﹤0.01% 637

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kemnay Advisory Services's CRSP Position: Q1 2026 in Review

Kemnay Advisory Services increased its CRISPR Therapeutics (CRSP) stake by 171% in Q1 2026, buying an estimated $25.5K and bringing the position to 767 shares worth $36.5K. The position accounts for 0.01% of the portfolio, ranked #372.

Kemnay Advisory Services first reported a position in CRSP in Q4 2025 and has held it in 2 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Kemnay Advisory Services held 767 shares of CRISPR Therapeutics worth $36.5K as of Q1 2026.
  • Kemnay Advisory Services bought 484 CRISPR Therapeutics shares in Q1 2026, an estimated $25.5K.
  • CRISPR Therapeutics made up 0.01% of Kemnay Advisory Services's portfolio in Q1 2026, its #372 holding.
  • Kemnay Advisory Services first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.